Board Member
aTYR PHARMA INC (ATYR)Equibles does not estimate personal net worth.
Get an email with a short summary when aTYR PHARMA INC publishes a filing, an earnings call transcript or a press release.
Get ATYR alertsEric Benevich is recorded as Board Member at aTYR PHARMA INC (ATYR). The newest filing on record that lists Eric Benevich as Board Member at aTYR PHARMA INC (ATYR) is dated March 26, 2026. aTYR PHARMA INC reported in an 8-K filed December 12, 2024 that Eric Benevich was appointed Class II director, effective December 10, 2024. The proxy statement of Neurocrine Biosciences Inc reports total compensation of $5,888,947 for Eric Benevich in fiscal 2025, including a base salary of $668,690. Disclosed compensation is on record for 7 fiscal years. Eric Benevich has spoken on 7 earnings calls and 1 other investor event across 1 company, most recently for Neurocrine Biosciences Inc on September 9, 2026. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. aTYR PHARMA INC is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kevin Gorman (CEO and Board Member), Kyle Gano, Ph.D. (CEO and Board Member), Kyle W. Gano (CEO and Board Member) and 7 others.
“On December 10, 2024, the Board of Directors (the "Board") of aTyr Pharma, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Eric Benevich to the Board, effective immediately.”
“I think the headline is that there's a lot of growth potential left in the VMAT2 category in tardive dyskinesia. If you think about Ingressa, it's an unusual brand, it's an unusual medicine in the sense that it's been on the market now for about nine and a half years and still growing at a double-digit clip.”
“Just five years ago, Neurocon was a single product commercial stage company celebrating Ingressa achieving blockbuster status, surpassing $1 billion in annual sales.”
“May 1st marked the nine-year anniversary of the Ingresa launch. It's remarkable that now, nine years post FDA approval and launch, we continue to deliver record new patient starts.”
“I'm very proud of our team's performance last year across both Crenicity and Ingreza, and I'm equally enthusiastic about the significant opportunity ahead for both brands.”
“Q3 was another banner quarter for our brands. Our commercial and medical teams continued to deliver with a record quarter for both INGREZZA and CRENESSITY with combined net sales of $785 million.”
Start not stated–present
Last confirmed March 26, 2026
Proxy statement
Start not stated–present
Last confirmed April 15, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Neurocrine Biosciences Inc (NBIX) | Chief Commercial Officer | $668,690 | $5,888,947 |
| 2024 | Neurocrine Biosciences Inc (NBIX) | Chief Commercial Officer | $636,848 | $6,306,164 |
| 2021 | Neurocrine Biosciences Inc (NBIX) | Chief Commercial Officer | $534,900 | $5,805,086 |
| 2020 | Neurocrine Biosciences Inc (NBIX) | Chief Commercial Officer | $499,900 | $6,748,960 |
| 2019 | Neurocrine Biosciences Inc (NBIX) | Chief Commercial Officer | $467,200 | $5,793,447 |
| 2018 | Neurocrine Biosciences Inc (NBIX) | Chief Commercial Officer | $432,600 | $3,672,605 |
| 2017 | Neurocrine Biosciences Inc (NBIX) | Chief Commercial Officer | $410,000 | $2,977,602 |
